KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Moderna (MRNA) Leases (2018 - 2026)

Moderna (MRNA) has disclosed Leases for 9 consecutive years, with $706.0 million as the latest value for Q1 2026.

  • For Q1 2026, Leases rose 1096.61% year-over-year to $706.0 million; the TTM value through Mar 2026 reached $706.0 million, up 1096.61%, while the annual FY2025 figure was $42.0 million, 94.47% down from the prior year.
  • Leases hit $706.0 million in Q1 2026 for Moderna, up from $42.0 million in the prior quarter.
  • Across five years, Leases topped out at $1.2 billion in Q3 2022 and bottomed at $42.0 million in Q4 2025.
  • Average Leases over 5 years is $657.6 million, with a median of $713.0 million recorded in 2023.
  • Year-over-year, Leases tumbled 94.47% in 2025 and then surged 1096.61% in 2026.
  • Moderna's Leases stood at $1.2 billion in 2022, then plummeted by 38.0% to $713.0 million in 2023, then grew by 6.45% to $759.0 million in 2024, then crashed by 94.47% to $42.0 million in 2025, then soared by 1580.95% to $706.0 million in 2026.
  • According to Business Quant data, Leases over the past three periods came in at $706.0 million, $42.0 million, and $47.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.